Kytril -->

Good day,
Good night,
Good morning

1 mg or 2 mg tablets and 1 mg/1 ml or 3 mg/3 ml solutions for injection

For acute nausea and vomiting in adults associated with:
CINV = Chemotherapy Induced Nausea & Vomiting1-4
RINV = Radiotherapy Induced Nausea & Vomiting1-4
PONV = Post-Operative Nausea & Vomiting3,4

A long half-life is the key to Kytril’s lasting action1–5

  • Ondansetron IV: half-life 4 hours – duration of effect of 12–24 hours5
  • Kytril IV: half-life 9 hours3-5 – duration of effect of more than 24 hours5
IV = Intravenous

When they need it most in CINV6

In patients receiving highly emetogenic chemotherapy including cisplatin6

Kytril 3 mg/ml IV or ondansetron 8 mg IV, plus dexamethasone 8 mg IV immediately prior to therapy.
Oral dexamethasone 4 mg three times a day on days 2 to 4 of therapy (n=21). Double-blind crossover study.6
Kytril “...is significantly better on day 2 when the majority of patients suffer most.“ 6
  • Palonosetron 0.25 mg IV and Kytril 1 mg/ml IV have similar effects on delayed nausea7
IV = Intravenous    CINV = Chemotherapy Induced Nausea & Vomiting

Kytril oral tablets offer reliable, lasting control in RINV8

Patients receiving hyperfractionated total body irradiation (TBI)
over a 4-day period8

p <0.01 vs. historic control for both treatment groups8
  • The proportion of patients with >5 emetic episodes over the 4 days was significantly less in the Kytril group (0%; p<0.01) but not in the ondansetron group (20%), vs. the control group (55.6%)8
Kytril 2 mg/ml (administered as two 1 mg tablets, n=18) was given once daily, 1 h prior to the administration of the first daily fraction of radiation. Ondansetron 8 mg (n=15) was given 1.5 h prior to every fraction of radiation (three times daily for days 0 to 3 and twice daily on day 4). Control did not receive a 5-HT3-receptor antagonist, (n=90)8. All patients had a diagnosis of either malignant disease or aplastic anaemia, and were hospitalised to receive 11 fractions each of 120 cGy of radiation over the course of 4 days for a total radiation exposure of 1320 cGy prior to bone marrow transplantation and the initiation of any conditioning chemotherapy.8
IV = Intravenous    RNIV = Radiotherapy Induced Nausea & Vomiting

Kytril IV controls PONV throughout the whole day9

Patients undergoing surgical procedures with spinal anaesthesia9

  • Kytril was significantly more effective in the late postoperative period (3-24 hours)9
  • A complete response (absence of nausea and vomiting) was seen in significantly more Kytril patients (86.7%, p<0.05) than ondansetron patients (60%)9
Patients undergoing gynaecological surgical procedures under spinal anaesthesia were randomised to two groups (each n=30): Kytril 2 mg/ml IV or ondansetron 4 mg IV 5 minutes before induction of anaesthesia9
IV = Intravenous    PONV = Post-Operative Nausea & Vomiting

Kytril has good tolerability1–4

  • The most commonly reported adverse reactions for Kytril (≥ 1/10) are headache and constipation, which may be transient
  • ECG changes including QT prolongation have been reported with Kytril and with other 5-HT3 antagonists
  • Other adverse events –
    Common (1/100 to <1/10): insomnia, diarrhoea, elevated hepatic transaminases (occurred at similar frequency to comparator therapy)
    Uncommon (1/1,000 to <1/100): hypersensitivity reactions, e.g. anaphylaxis, urticaria, extrapyrimidal reactions, serotonin syndrome, rash

References

  1. Kytril 1 mg film-coated tablets Summary of Product Characteristics.
  2. Kytril 2 mg film-coated tablets Summary of Product Characteristics.
  3. Kytril 1 mg/ml solution for injection Summary of Product Characteristics.
  4. Kytril 3 mg/ml solution for injection Summary of Product Characteristics.
  5. Savant K, Khandeparker RVS, Berwal V, et al. J Korean Assoc Oral Maxillofac Surg 2016;42:84–89.
  1. Stewart L, Crawford SM, Taylor PA. The Pharm J 2000; 265(No. 7104):59–62.
  2. Roscoe JA, Heckler CE, Morrow GR, et al. J Clin Oncol 2012;30(27):3389–3395.
  3. Spitzer TR, Friedman CJ, Bushnell W, et al. Bone Marrow Transplantation 2000;26:203–210.
  4. Makker R, Bhardwaj A, Singh AP, Anand A. Int J Med and Dent Sci 2017;6(1):1371–1375.

Downloads

Abbreviated prescribing
information
Summary of Product
Characteristics – 1mg Tablet
Summary of Product
Characteristics – 2mg Tablet
Summary of Product
Characteristics – 1mg Ampoule
Summary of Product
Characteristics – 3mg Ampoule
Patient information leaflet –
1mg Tablet
Patient information leaflet –
2mg Tablet
Patient information leaflet –
1mg Ampoule
Patient information leaflet –
3mg Ampoule

Contact Us

Adverse event reporting

Adverse events should be reported. For the UK reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. For the ROI, Healthcare professionals are asked to report any suspected adverse reactions to HPRA Pharmacovigilance, Earlsfort Terrace, IRL-Dublin 2
Tel: +353 1 6764971 Website: www.hpra.ie. Adverse events should also be reported to Pharmanovia, c/o Atnahs Pharma UK Limited on +44 (0) 1279 406759, or by email to atnahspv@diamondpharmaservices.com